Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Accelerated market share gains in structural heart (WATCHMAN) and endoscopy, coupled with successful synergistic acquisitions, drive revenue growth above peers while scaling margins.
Multiple Compression to Peer Median: Premium valuation collapses as the market forces reversion to peer median PEG ratios.
Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion.
Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion.
High switching costs in implantable MedSurg devices.
Intangible assets via robust IP in structural heart (WATCHMAN).
Demographic tailwinds and deferred elective procedure catch-up drive sustained, above-trend cardiovascular demand.
BSX is rated Buy at the report-date price of $54.10 versus our fair value of $70.39, with +30.11% potential return.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
A severe macro shock testing hospital capital budgets exposes operating leverage risks. With high fixed costs and a reinvestment rate of 82.6%, a top-line deceleration below 6% rapidly compresses the 20% operating margin, forcing fair value down toward the $55.91 bear floor.
High switching costs in implantable MedSurg devices.
Intangible assets via robust IP in structural heart (WATCHMAN).
Scale economies driving durable 19.7% trailing operating margins.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $3.4B after capex $1.1B, with terminal value at 67.5% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If Y1-Y2 revenue growth tracks 8.0-8.9% with 20% margins, base $70.39 holds.
If Y1-Y2 revenue growth tracks 8.0-8.9% with 20% margins, base $70.39 holds.
If Y1-Y2 revenue growth tracks 8.0-8.9% with 20% margins, base $70.39 holds.
If Y1-Y2 revenue growth tracks 8.0-8.9% with 20% margins, base $70.39 holds.
Normal capex phase (Capex/DA at 0.82) allows exceptional free cash flow conversion without aggressive reinvestment drags.
Demographic tailwinds and deferred elective procedure catch-up drive sustained, above-trend cardiovascular demand.
Hospital capital constraints limit equipment adoption and pressure pricing on commoditized consumables.
Normal capex phase (Capex/DA at 0.82) allows exceptional free cash flow conversion without aggressive reinvestment drags.
Trim exposure if top-line revenue growth formally breaches the 6% falsification trigger or if multiple premiums fully compress.
Strong-buy. The composite fair value of $70.39 effectively bridges valuation cross-checks optimism with internal fundamental constraints, supported by reliable discounted earnings models.
internal valuation cross-checks ($85.19) heavily anchors on near-term beats; our internal models impose a disciplined terminal constraint via the multi-stage moat fade model ($64.74).
Buy. The composite fair value of $70.39 effectively bridges valuation cross-checks optimism with internal fundamental constraints, supported by reliable discounted earnings models.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Regulatory setbacks, intense competition in cardiac rhythm management, and price erosion from hospital consolidation or Medicare reimbursement cuts compress margins and slow growth.
Premium valuation collapses as the market forces reversion to peer median PEG ratios.
Medicare reimbursement cuts and hospital consolidation severely erode structural pricing power.
Accelerated market share gains in the structural heart segment fail, normalizing revenue growth abruptly.
The five developments that would weaken our investment case.
Slowing revenue expansion indicates that market adoption in structural heart and electrophysiology product categories has peaked, eliminating the growth premium that sustains the premium valuation.
Current:19.9% for the period ended 2025-12-31
Alert if< 6.0% over any trailing twelve-month period
Operating margin slippage demonstrates that fixed manufacturing overhead and clinical compliance expenditures are overwhelming gross profits, exposing corporate vulnerability to operating cost deleverage.
Current:19.8% for the period ended 2025-12-31
Alert if< 18.0% over any two consecutive fiscal quarters
Sub-par return on capital illustrates that capital deployed across tuck-in acquisitions is generating inadequate economic spread, prompting multiple compression toward medical technology peer medians.
Current:8.3% as of 2026-05-12
Alert if< 7.0% over any trailing twelve-month period
Gross margin erosion signals reimbursement reductions from public healthcare payors and adverse product mix shifts, directly impairing unit gross profits across core cardiovascular therapy categories.
Current:69.0% for the period ended 2025-12-31
Alert if< 66.0% over any fiscal quarter
Inadequate cash conversion indicates that reported net earnings are burdened by working capital absorption and deferred milestone outlays, curtailing self-funded strategic acquisition capabilities.
Current:1.565 as of 2026-05-12
Alert if< 1.000 over any full fiscal year
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Accelerated market share gains in structural heart (WATCHMAN) and endoscopy, coupled with successful synergistic acquisitions, drive revenue growth above peers while scaling margins.
Maintains mature compounder trajectory, benefiting from a diverse portfolio across cardiovascular and MedSurg, generating strong operating cash flows and consistent margin expansion.
Warning level: < 6.0% over any trailing twelve-month period. Slowing revenue expansion indicates that market adoption in structural heart and electrophysiology product categories has peaked, eliminating the growth premium that sustains the premium valuation.
Warning level: < 18.0% over any two consecutive fiscal quarters. Operating margin slippage demonstrates that fixed manufacturing overhead and clinical compliance expenditures are overwhelming gross profits, exposing corporate vulnerability to operating cost deleverage.
Warning level: < 7.0% over any trailing twelve-month period. Sub-par return on capital illustrates that capital deployed across tuck-in acquisitions is generating inadequate economic spread, prompting multiple compression toward medical technology peer medians.
Warning level: < 66.0% over any fiscal quarter. Gross margin erosion signals reimbursement reductions from public healthcare payors and adverse product mix shifts, directly impairing unit gross profits across core cardiovascular therapy categories.
Warning level: < 1.000 over any full fiscal year. Inadequate cash conversion indicates that reported net earnings are burdened by working capital absorption and deferred milestone outlays, curtailing self-funded strategic acquisition capabilities.
| $11.89B |
| $12.68B |
| $14.24B |
| $16.75B |
| $20.07B |
| +14.0% |
| Gross profit | $8.18B | $8.73B | $9.90B | $11.49B | $13.85B | +14.1% |
| Operating income | $1.42B | $1.61B | $2.25B | $2.59B | $3.73B | +27.4% |
| Net income | $1.04B | $698.0M | $1.59B | $1.85B | $2.90B | +29.2% |
| EPS (diluted) | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 | +29.5% |
| EBITDA | $2.51B | $2.75B | $3.45B | $3.86B | $5.10B | +19.4% |
| R&D | $1.20B | $1.32B | $1.41B | $1.62B | $2.05B | +14.3% |
| SG&A | $4.36B | $4.52B | $5.19B | $5.98B | $6.89B | +12.1% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 20,074,000,000 |
|---|---|
| Cost of revenue | 6,221,000,000 |
| Gross profit | 13,853,000,000 |
| Operating expenses | 9,882,000,000 |
| Operating income | 3,971,000,000 |
| Non-operating items and tax | -1,073,000,000 |
| Net income | 2,898,000,000 |
| Total assets | 43,673,000,000 |
|---|---|
| Cash | 1,965,000,000 |
| Current assets | 8,794,000,000 |
| Total liabilities | 19,201,000,000 |
| Current liabilities | 5,439,000,000 |
| Shareholders’ equity | 24,232,000,000 |
Point-in-time financial data used in the 2026-05-12 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 11.9B | 2.5B | 1B | 1.9B | 1.3B | 554M | 1.1B | 194M | 0 | 55M | 0 | — | — | — | — | 1.9B | 9.5B | 15.3% | — | 4.9% | — |
| 2022-12-31 | 12.7B | 2.7B | 698M | 1.5B | 914M | 612M | 1.1B | 220M | 0 | 55M | -165M | — | — | — | — | 928M | 9.3B | 16.0% | — | 7.1% | — |
| 2023-12-31 | 14.2B | 3.4B | 1.6B | 2.5B | 1.7B | 800M | 1.2B | 233M | — | 28M | -4M | — | — | — | — | 865M | 9.5B | 17.0% | — | 7.2% | — |
| 2024-12-31 | 16.7B | 3.9B | 1.9B | 3.4B | 2.4B | 1.1B | 1.3B | 266M | — | 0 | 1.8B | — | — | — | — | 414M | 10.7B | 17.9% | — | 8.1% | — |
| 2025-12-31 | 20.1B | 5.1B | 2.9B | 4.5B | 3.4B | 1.1B | 1.4B | 299M | — | — | -491M | — | — | — | — | 2B | 11.4B | 19.8% | — | 7.7% | — |
BSX trades at 14.4x forward earnings against a peer median of 13.6x; EV/EBITDA of 16.2x against a peer median of 14.6x; 6 peers.
| Level | Action |
|---|---|
| Thesis break | Trim exposure if top-line revenue growth formally breaches the 6% falsification trigger or if multiple premiums fully compress. |
| Stryker Corporation |
| 17.6x |
| 4.5x |
| 17.3x |
| 15.2% |
| 17.8% |
| MDT | Medtronic plc | 12.3x | 2.7x | 12.2x | 9.4% | 20.0% |
| EW | Edwards Lifesciences Corporation | 22.9x | 7.0x | 22.6x | 10.5% | 31.2% |
| GEHC | GE HealthCare Technologies Inc. | 11.5x | 1.3x | 10.4x | 19.5% | 11.1% |
